1/9
08:02 am
rani
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Low
Report
Rani Therapeutics (NASDAQ:RANI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
1/8
07:00 am
rani
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
Low
Report
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
12/30
04:14 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
04:33 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
04:05 pm
rani
Rani Therapeutics to Participate in the Evercore Healthcare Conference
Medium
Report
Rani Therapeutics to Participate in the Evercore Healthcare Conference
11/21
02:05 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
05:51 pm
rani
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]
Medium
Report
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight [Yahoo! Finance]
11/6
04:30 pm
rani
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Medium
Report
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
10/31
01:05 pm
rani
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Rani Therapeutics (NASDAQ:RANI) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/30
08:00 am
rani
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
High
Report
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
10/26
06:31 am
rani
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential [Yahoo! Finance]
Medium
Report
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential [Yahoo! Finance]